Skip to Content

Promising Findings for R/R Large B-Cell Lymphoma – Glofitama and Epcoritamab Show Curative Potential

Martin Hutchings, senior consultant at Rigshospitalet, Copenhagen, elaborates on studies presented at EHA23, ASCO23, and in Lugano, providing sufficient follow-up results on patients with relapsed/refractory (R/R) large B-cell lymphoma who received glofitamab or epcoritamab. Based on these findings, there is compelling evidence to suggest that these CD3 × CD20 bispecific antibodies possess curative potential.

Få tillgång

Om du är läkare, sjuksköterska eller annan vårdpersonal kan du komma åt hela artikeln genom att skapa en profil på BestPractice Nordic.

Back to top